These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38669473)

  • 1. Contemporary Management of Obesity: A Comparison of Bariatric Metabolic Surgery and Novel Incretin Mimetic Drugs.
    Singh A; Nissen SE
    Diabetes Technol Ther; 2024 Sep; 26(9):673-685. PubMed ID: 38669473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
    Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
    Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirzepatide for Weight Loss: Can Medical Therapy "Outweigh" Bariatric Surgery?
    Novograd J; Mullally JA; Frishman WH
    Cardiol Rev; 2023 Sep-Oct 01; 31(5):278-283. PubMed ID: 36688833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
    Rohde U
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity Management in Adults: A Review.
    Elmaleh-Sachs A; Schwartz JL; Bramante CT; Nicklas JM; Gudzune KA; Jay M
    JAMA; 2023 Nov; 330(20):2000-2015. PubMed ID: 38015216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management.
    Alhomoud IS; Talasaz AH; Chandrasekaran P; Brown R; Mehta A; Dixon DL
    Pharmacotherapy; 2024 Sep; ():. PubMed ID: 39225417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the treatment of obesity.
    Blüher M; Aras M; Aronne LJ; Batterham RL; Giorgino F; Ji L; Pietiläinen KH; Schnell O; Tonchevska E; Wilding JPH
    Diabetes Obes Metab; 2023 Aug; 25(8):2058-2072. PubMed ID: 37055715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches.
    Morissette A; Mulvihill EE
    J Pharm Pharm Sci; 2024; 27():13065. PubMed ID: 38903652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
    Ard J; Fitch A; Fruh S; Herman L
    Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.
    Jakubowska A; Roux CWL; Viljoen A
    Endocrinol Metab (Seoul); 2024 Feb; 39(1):12-22. PubMed ID: 38356208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
    Ordóñez-Vázquez AL; Beltrán-Gall SM; Pal SC; Méndez-Sánchez N
    Med Sci Monit; 2022 Sep; 28():e938365. PubMed ID: 36093924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.
    Huang X; Liu J; Peng G; Lu M; Zhou Z; Jiang N; Yan Z
    J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38916409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of Weight-loss and Obesity with a Focus on GLP 1-Receptor Agonists.
    Myerson M; Paparodis RD
    J Clin Pharmacol; 2024 Oct; 64(10):1204-1221. PubMed ID: 38924121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
    Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
    Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
    Kaplan JM; Zaman A; Abushamat LA
    Curr Cardiol Rep; 2024 Sep; 26(9):1011-1019. PubMed ID: 39031282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.